{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T05:47:30Z","timestamp":1793771250120,"version":"4.6.1"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T00:00:00Z","timestamp":1596758400000},"content-version":"vor","delay-in-days":219,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/igo\/"}],"funder":[{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception: X"],"published-print":{"date-parts":[[2020]]},"DOI":"10.1016\/j.conx.2020.100037","type":"journal-article","created":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T02:27:39Z","timestamp":1597890459000},"page":"100037","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Medical regimens for abortion at 12\u202fweeks and above: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"2","author":[{"given":"Katherine","family":"Whitehouse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Brant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marita Sporstol","family":"Fonhus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Lavelanet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bela","family":"Ganatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.conx.2020.100037_bb0005","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/S0140-6736(17)31794-4","article-title":"Global, regional, and subregional classification of abortions by safety, 2010\u201314: estimates from a Bayesian hierarchical model","volume":"390","author":"Ganatra","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.conx.2020.100037_bb0010","series-title":"Abortion worldwide 2017: uneven progress and unequal access In: New York: Guttmacher Institute","author":"Singh","year":"2018"},{"key":"10.1016\/j.conx.2020.100037_bb0015","series-title":"Safe abortion\u202f: technical and policy guidance for health systems","author":"World Health Organization","year":"2012"},{"issue":"1","key":"10.1016\/j.conx.2020.100037_bb0020","article-title":"Medical methods for mid-trimester termination of pregnancy","volume":"19","author":"Wildschut","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.conx.2020.100037_bb0025","unstructured":"Veritas Health Innovation. Covidence systematic review software. In: Melbourne, Australia. Available at www.covidence.org."},{"key":"10.1016\/j.conx.2020.100037_bb0030","series-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2019"},{"key":"10.1016\/j.conx.2020.100037_bb0035","series-title":"Edited by The Nordic Cochrane Centre TCC. 5.3 ed. Copenhagen","author":"Review Manager (RevMan)","year":"2014"},{"key":"10.1016\/j.conx.2020.100037_bb0040","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.conx.2020.100037_bb0045","series-title":"GRADEpro GDT: GRADEpro guideline development tool [software]","year":"2015"},{"key":"10.1016\/j.conx.2020.100037_bb0050","series-title":"Medical management of abortion. Geneva,Switzerland","author":"World Health Organization","year":"2018"},{"key":"10.1016\/j.conx.2020.100037_bb0055","series-title":"Handbook for guideline development Geneva, Switzerland","author":"World Health Organization","year":"2010"},{"key":"10.1016\/j.conx.2020.100037_bb0060","article-title":"World Bank list of economies","author":"World Bank","year":"2018"},{"key":"10.1016\/j.conx.2020.100037_bb0065","first-page":"101","article-title":"Mifepristone in combination with misoprostol for the termination of pregnancy at 8\u201316 weeks\u2019 gestational age: a multicentre randomized controlled trial","volume":"24","author":"Chen","year":"2013","journal-title":"Journal of Reproduction and Contraception"},{"key":"10.1016\/j.conx.2020.100037_bb0070","first-page":"505","article-title":"Efficacy and safety of mifepristone combined with misoprostol for termination of pregnancy; between 8 and 16 weeks of gestation","author":"Jinfeng","year":"2015","journal-title":"Zhonghua Fu Chan Ke Za Zhi"},{"key":"10.1016\/j.conx.2020.100037_bb0075","series-title":"Personal communication: Mifepristone and misoprostol for the termination of pregnancy at 64\u2013140 days since LMP","author":"Naravage","year":"2018"},{"key":"10.1016\/j.conx.2020.100037_bb0080","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.contraception.2009.12.018","article-title":"Randomized trial of buccal versus vaginal misoprostol for induction of second trimester abortion","volume":"81","author":"Ellis","year":"2010","journal-title":"Contraception"},{"key":"10.1016\/j.conx.2020.100037_bb0085","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1097\/01.AOG.0000289577.32274.a5","article-title":"Mifepristone in second-trimester medical abortion: a randomized controlled trial","volume":"110","author":"Kapp","year":"2007","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.conx.2020.100037_bb0090","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.ajog.2003.09.037","article-title":"Randomized controlled trial of misoprostol for second-trimester pregnancy termination associated with fetal malformation","volume":"190","author":"Akoury","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.conx.2020.100037_bb0095","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s13224-015-0827-1","article-title":"Second trimester medical termination of pregnancy with combined intracervical and intravaginal misoprostol: comparative analysis with intravaginal misoprostol \u2014 a pilot study","author":"Desai","year":"2016","journal-title":"J Obstet Gynaecol India"},{"key":"10.1016\/j.conx.2020.100037_bb0100","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1097\/AOG.0000000000000290","article-title":"Mifepristone and oral, vaginal, or sublingual misoprostol for second-trimester abortion: a randomized controlled trial","volume":"123","author":"Dickinson","year":"2014","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.conx.2020.100037_bb0105","first-page":"1294","article-title":"A comparison of oral misoprostol with vaginal misoprostol administration in second-trimester pregnancy termination for fetal abnormality","volume":"101","author":"Dickinson","year":"2003","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.conx.2020.100037_bb0110","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1111\/j.1471-0528.2005.00727.x","article-title":"A randomised controlled trial of 6 and 12 hourly administration of vaginal misoprostol for second trimester pregnancy termination","volume":"112","author":"Herabutya","year":"2005","journal-title":"BJOG"},{"key":"10.1016\/j.conx.2020.100037_bb0115","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ijgo.2010.06.008","article-title":"One- and two-day mifepristone-misoprostol intervals for second trimester termination of pregnancy between 13 and 16 weeks of gestation","author":"Hou","year":"2010","journal-title":"Int J Gynecol Obstet"},{"key":"10.1016\/j.conx.2020.100037_bb0120","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1093\/humrep\/der218","article-title":"One- and two-day dosing intervals between mifepristone and misoprostol in second trimester medical termination of pregnancy \u2014 a randomized trial","author":"Mentula","year":"2011","journal-title":"Hum Reprod"},{"key":"10.1016\/j.conx.2020.100037_bb0125","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s13224-016-0869-z","article-title":"A comparative study of misoprostol only and mifepristone plus misoprostol in second trimester termination of pregnancy","volume":"66","author":"Akkenapally","year":"2016","journal-title":"J Obstet Gynaecol India"},{"key":"10.1016\/j.conx.2020.100037_bb0130","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ijgo.2015.02.023","article-title":"A double-blind randomized controlled trial of mifepristone or placebo before buccal misoprostol for abortion at 14\u201321 weeks of pregnancy","author":"Dabash","year":"2015","journal-title":"Int J Gynecol Obstet"},{"key":"10.1016\/j.conx.2020.100037_bb0135","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s13224-013-0472-5","article-title":"Pre-induction with mifepristone for second trimester termination of pregnancy","author":"Kulkarni","year":"2014","journal-title":"J Obstet Gynaecol India"},{"key":"10.1016\/j.conx.2020.100037_bb0140","doi-asserted-by":"crossref","first-page":"25","DOI":"10.5005\/jp-journals-10006-1166","article-title":"Second trimester abortion with vaginal misoprostol: is there any advantage with prior mifepristone priming? A comparative study","author":"Mukhopadhyay","year":"2012","journal-title":"South Asian Federation of Obstetrics and Gynaecology"},{"key":"10.1016\/j.conx.2020.100037_bb0145","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s13224-011-0118-4","article-title":"Misoprostol vs mifepristone and misoprostol in second trimester termination of pregnancy","author":"Nagaria","year":"2011","journal-title":"J Obstet Gynaecol India"},{"key":"10.1016\/j.conx.2020.100037_bb0150","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/AOG.0b013e318227214e","article-title":"Mifepristone and misoprostol compared with misoprostol alone for second-trimester abortion: a randomized controlled trial","volume":"118","author":"Ngoc","year":"2011","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.conx.2020.100037_bb0155","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1097\/AOG.0000000000001688","article-title":"Simultaneous administration compared with a 24-hour mifepristone-misoprostol interval in second-trimester abortion","volume":"128","author":"Abbas","year":"2016","journal-title":"Obstet Gynecology"},{"key":"10.1016\/j.conx.2020.100037_bb0160","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1093\/humrep\/den425","article-title":"A randomized trial to compare two dosing intervals of misoprostol following mifepristone administration in second trimester medical abortion","author":"Chai","year":"2009","journal-title":"Human Reprod"},{"key":"10.1016\/j.conx.2020.100037_bb0165","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ijgo.2013.08.009","article-title":"Dosing interval of 24 hours versus 48 hours between mifepristone and misoprostol administration for mid-trimester termination of pregnancy","author":"Chaudhuri","year":"2014","journal-title":"Obstet Gynecol Int J"},{"key":"10.1016\/j.conx.2020.100037_bb0170","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/j.1471-0528.1996.tb09842.x","article-title":"A comparison of 600 and 200 mg mifepristone prior to second trimester abortion with the prostaglandin misoprostol","volume":"103","author":"Webster","year":"1996","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/j.conx.2020.100037_bb0175","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/oxfordjournals.humrep.a135965","article-title":"Induction of abortion in the second trimester by a combination of misoprostol and mifepristone: a randomized comparison between two misoprostol regimens","volume":"10","author":"el-Refaey","year":"1995","journal-title":"Hum Reprod"},{"key":"10.1016\/j.conx.2020.100037_bb0180","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0029-7844(97)00419-5","article-title":"Vaginal misoprostol compared with oral misoprostol in termination of second-trimester pregnancy","volume":"90","author":"Ho","year":"1997","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.conx.2020.100037_bb0185","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1093\/humrep\/15.10.2205","article-title":"Randomized comparison of vaginal (200 microg every 3 h) and oral (400 microg every 3 h) misoprostol when combined with mifepristone in termination of second trimester pregnancy","volume":"15","author":"Ngai","year":"2000","journal-title":"Hum Reprod"},{"key":"10.1016\/j.conx.2020.100037_bb0190","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1093\/humrep\/dei196","article-title":"A prospective randomized comparison of sublingual and oral misoprostol when combined with mifepristone for medical abortion at 12\u201320 weeks gestation","volume":"20","author":"Tang","year":"2005","journal-title":"Hum Reprod"},{"key":"10.1016\/j.conx.2020.100037_bb0195","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1093\/humrep\/dei037","article-title":"A randomized trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion at 13\u201320 weeks gestation","volume":"20","author":"Hamoda","year":"2005","journal-title":"Hum Reprod"},{"key":"10.1016\/j.conx.2020.100037_bb0200","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s13224-014-0605-5","article-title":"Buccal versus vaginal misoprostol administration for the induction of first and second trimester abortions","author":"Garg","year":"2015","journal-title":"J Obstet Gynaecol India"},{"key":"10.1016\/j.conx.2020.100037_bb0205","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.contraception.2017.02.004","article-title":"A randomized controlled trial comparing repeat doses of 400 mcg sublingual to buccal misoprostol after mifepristone for termination of pregnancy 13\u201321 weeks","volume":"95","author":"Dabash","year":"2017","journal-title":"Contraception"},{"key":"10.1016\/j.conx.2020.100037_bb0210","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/jfprhc-2016-101652","article-title":"Comparing two regimens of intravaginal misoprostol with intravaginal gemeprost for second-trimester pregnancy termination: a randomised controlled trial","volume":"43","author":"Koh","year":"2017","journal-title":"J Fam Plann Reprod Health Care"},{"key":"10.1016\/j.conx.2020.100037_bb0215","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/humrep\/15.3.709","article-title":"A comparison of two regimens of intravaginal misoprostol for termination of second trimester pregnancy: a randomized comparative trial","volume":"15","author":"Wong","year":"2000","journal-title":"Hum Reprod"},{"key":"10.1016\/j.conx.2020.100037_bb0220","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1258\/td.2010.100018","article-title":"A comparison of two regimens of misoprostol for second trimester medical termination of pregnancy: a randomized trial","author":"Chaudhuri","year":"2010","journal-title":"Trop Doct"},{"key":"10.1016\/j.conx.2020.100037_bb0225","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00404-011-1949-z","article-title":"A randomized comparative study on vaginal administration of acetic acid-moistened versus dry misoprostol for mid-trimester pregnancy termination","author":"Bhattacharjee","year":"2012","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.conx.2020.100037_bb0230","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/j.1447-0756.2010.01458.x","article-title":"Randomized controlled study comparing misoprostol moistened with normal saline and with acetic acid for second-trimester pregnancy termination. Is it different?","author":"Pongsatha","year":"2011","journal-title":"J Obstet Gynaecol Res"},{"key":"10.1016\/j.conx.2020.100037_bb0235","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.contraception.2007.09.007","article-title":"Second-trimester pregnancy termination with 600-\u03bcg vs. 400-\u03bcg vaginal misoprostol and systematic curettage postexpulsion: a randomized trial","volume":"77","author":"Carbonell","year":"2008","journal-title":"Contraception"},{"key":"10.1016\/j.conx.2020.100037_bb0240","first-page":"245","article-title":"A comparison of low-dose and high-dose protocols of vaginal misoprostol for second trimester termination of pregnancy","volume":"36","author":"Ozerkan","year":"2009","journal-title":"Clin Exp Obstet Gynecol"},{"key":"10.1016\/j.conx.2020.100037_bb0245","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1479-828X.2001.tb01318.x","article-title":"A randomised trial of oral versus vaginal administration of misoprostol for the purpose of mid-trimester termination of pregnancy","volume":"41","author":"Gilbert","year":"2001","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"10.1016\/j.conx.2020.100037_bb0250","first-page":"1","article-title":"Comparative study of misoprostol in first and second trimester abortions by oral, sublingual, and vaginal routes","volume":"65","author":"Nautiyal","year":"2014","journal-title":"J Obstet Gynaecol India"},{"key":"10.1016\/j.conx.2020.100037_bb0255","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1479-828X.2008.00831.x","article-title":"A randomised comparative study on sublingual versus vaginal administration of misoprostol for termination of pregnancy between 13 to 20 weeks","volume":"48","author":"Bhattacharjee","year":"2008","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"10.1016\/j.conx.2020.100037_bb0260","doi-asserted-by":"crossref","first-page":"751","DOI":"10.4236\/ojog.2014.413104","article-title":"Comparative study of sublingual and vaginal misoprostol in second trimester induced abortion","volume":"4","author":"Modak","year":"2014","journal-title":"Open J Obstet Gynecol"},{"key":"10.1016\/j.conx.2020.100037_bb0265","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/humrep\/den328","article-title":"Comparison of vaginal and sublingual misoprostol for second trimester abortion: randomized controlled equivalence trial","volume":"24","author":"Von Hertzen","year":"2009","journal-title":"Human Reprod"},{"key":"10.1016\/j.conx.2020.100037_bb0270","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/AOG.0000000000000946","article-title":"Vaginal misoprostol compared with buccal misoprostol for termination of second-trimester pregnancy: a randomized controlled trial","volume":"126","author":"Al","year":"2015","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.conx.2020.100037_bb0275","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1111\/j.1471-0528.2004.00222.x","article-title":"A prospective randomised comparison of sublingual and vaginal misoprostol in second trimester termination of pregnancy","volume":"111","author":"Tang","year":"2004","journal-title":"BJOG"},{"key":"10.1016\/j.conx.2020.100037_bb0280","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1097\/01.AOG.0000431056.79334.cc","article-title":"135: second-trimester abortion","volume":"121","author":"practice bulletin no","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.conx.2020.100037_bb0285","series-title":"Clinical updates in reproductive health","author":"Ipas","year":"2018"},{"key":"10.1016\/j.conx.2020.100037_bb0290","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1080\/13625187.2016.1258461","article-title":"Second trimester medical abortion with mifepristone followed by unlimited dosing of buccal misoprostol in Armenia","volume":"22","author":"Louie","year":"2017","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.conx.2020.100037_bb0295","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/01.AOG.0000230398.32794.9d","article-title":"Misoprostol administered by epithelial routes: drug absorption and uterine response","volume":"108","author":"Meckstroth","year":"2006","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.conx.2020.100037_bb0300","doi-asserted-by":"crossref","first-page":"S160","DOI":"10.1016\/j.ijgo.2007.09.004","article-title":"Misoprostol: pharmacokinetic profiles, effects on the uterus and side-effects","volume":"99","author":"Tang","year":"2007","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.conx.2020.100037_bb0305","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1067\/mob.2002.123887","article-title":"A comparison of medical induction and dilation and evacuation for second-trimester abortion","volume":"187","author":"Autry","year":"2002","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.conx.2020.100037_bb0310","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1097\/AOG.0b013e31820c3d26","article-title":"Second-trimester abortion for fetal anomalies or fetal death: labor induction compared with dilation and evacuation","volume":"117","author":"Bryant","year":"2011","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.conx.2020.100037_bb0315","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/1472-6963-11-224","article-title":"Surgical and medical second trimester abortion in South Africa: a cross-sectional study","volume":"11","author":"Grossman","year":"2011","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.conx.2020.100037_bb0320","doi-asserted-by":"crossref","first-page":"386 e381","DOI":"10.1016\/j.ajog.2011.07.028","article-title":"Midtrimester dilation and evacuation versus prostaglandin induction: a comparison of composite outcomes","volume":"205","author":"Whitley","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.conx.2020.100037_bb0325","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1097\/AOG.0b013e31819dbfe2","article-title":"Uterine rupture in second-trimester misoprostol-induced abortion after cesarean delivery: a systematic review","volume":"113","author":"Goyal","year":"2009","journal-title":"Obstet Gynecol"}],"container-title":["Contraception: X"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590151620300204?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590151620300204?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T02:33:54Z","timestamp":1762914834000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590151620300204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":65,"alternative-id":["S2590151620300204"],"URL":"https:\/\/doi.org\/10.1016\/j.conx.2020.100037","relation":{},"ISSN":["2590-1516"],"issn-type":[{"value":"2590-1516","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medical regimens for abortion at 12\u202fweeks and above: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Contraception: X","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.conx.2020.100037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 World Health Organization; licensee Elsevier.","name":"copyright","label":"Copyright"}],"article-number":"100037"}}